AlloCare - Support and Management of Late Effects After Allogeneic Hematopoietic Stem Cell Transplantation

Recruiting now · Not applicable

Conditions studied: Hematological Diseases

In brief

A developed multimodal intervention targeting late effects in survivors of allogeneic hematopoietic stem cell transplantation (allo-HSCT) will be evaluated in a two-arm randomized controlled trial with an internal pilot phase.

Key facts

Study ID

NCT06281496

Run by

Rigshospitalet, Denmark

People needed

100

Starts

2024-11-01

Expected to finish

2027-12-01

Last updated by the study team

2025-08-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult patients (age> 18 years) treated with myeloablative or non-myeloablative HSCT in outpatient follow-up without recurrent disease are eligible for inclusion.

You may not qualify if…

• Patients with recurrence or subsequent malignancy requiring cancer treatment or lack of access to email and the Internet will be excluded.

Where it is running

• Rigshospitalet — Copenhagen, Denmark (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.